Alembic Pharmaceuticals Receives USFDA Approval to Market Generic Antidepressant Drug

Alembic Pharmaceuticals has announced that it has received approval from the United States Food and Drug Administration (USFDA) to market a generic version of an antidepressant drug, Vortioxetine Hydrobromide tablets.

The medication is a generic equivalent of Trintellix tablets, which are used to treat depression.The approval granted to Alembic by the USFDA allows the company to market and sell the medication in the United States.

According to the company’s press release, Vortioxetine Hydrobromide tablets have an estimated market size of $466 million for the 12 months ending December 2020.The medication will be manufactured at Alembic’s facility located in Gujarat, India.

The company has a portfolio of over 120 generic drugs, and the addition of Vortioxetine Hydrobromide tablets is expected to further strengthen its position in the US generic drug market.The approval of Vortioxetine Hydrobromide tablets by the USFDA is a significant achievement for Alembic Pharmaceuticals and demonstrates its commitment to bringing affordable and high-quality generic drugs to the market.

The company has stated that it will continue to focus on developing and launching more such products in the future.With this approval, Alembic Pharmaceuticals is well-positioned to take advantage of the growing demand for generic drugs in the United States and contribute to making healthcare more accessible and affordable for patients.